Decibel Therapeutics, Inc. (DBTX)
| Market Cap | 182.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 24.87M |
| EPS (ttm) | -3.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,726 |
| Open | 7.65 |
| Previous Close | 7.38 |
| Day's Range | 7.25 - 7.68 |
| 52-Week Range | 6.18 - 24.39 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 9, 2021 |
About DBTX
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance...
Financial Performance
Financial StatementsNews
Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics' Hearing Loss Gene Therapy Receives FDA Orphan Drug Tag
The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to Decibel Therapeutics Inc (NASDAQ: DBTX) lead gene therapy product candidate, DB-OTO, for otoferlin-related cong...
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Oto...
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
- Bolstered Board of Directors and Scientific Advisory Board with key appointments -
Losers Outnumber Gainers in Biotech IPOs This Year
Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.
Decibel Therapeutics Expands World-Class Scientific Advisory Board
Adds leaders with expertise in hearing loss and balance disorders, combined with experience in gene therapy development Adds leaders with expertise in hearing loss and balance disorders, combined with e...
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and impr...
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO –
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and im...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds-
Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies
Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at the Annual...
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Pr...
Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference Podium presentations and posters shared at the 44th Annual Association for Research in Ot...
The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and imp...
Decibel Therapeutics Announces Pricing of Initial Public Offering Nasdaq:DBTX
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and...
Catalent and Decibel Team Up to Develop Gene Therapy for Congenital Hearing Loss
Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.
Invitae, Decibel Therapeutics Launch Free Testing Program for Congenital Hearing Loss
Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.
Hearing disorder biotech Decibel Therapeutics files for a $75 million IPO
Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
Decibel Therapeutics IPO Registration Document (S-1)
Decibel Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Manufacturers News
...Decibel Therapeutics announced the closing of an oversubscribed Series D financing, which raised $82.2M.
Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug Administration
BOSTON--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that th...